Tags

Type your tag names separated by a space and hit enter

Metabolic abnormalities of apolipoprotein B-containing lipoproteins in non-insulin-dependent diabetes: a stable isotope kinetic study.
Eur J Clin Invest. 2000 Aug; 30(8):685-94.EJ

Abstract

BACKGROUND

Kinetic abnormalities of apolipoprotein B (apoB)-containing lipoproteins in noninsulin-dependent diabetes mellitus (NIDDM) remain poorly understood. To get further insight into these abnormalities we performed a stable isotope kinetic experiment comparing the metabolism of apoB-containing lipoproteins in moderately severe NIDDM patients and healthy control subjects.

METHODS

The study was performed in the fed state. Subjects underwent a primed infusion of 0.7 mg kg(-1) of L-[1-(13)C]leucine followed by a 16-h constant infusion of 0.7 mg kg(-1) h(-1). [13C]Leucine enrichment in apoB was measured by gas chromatography/combustion/isotope ratio mass spectrometry.

RESULTS

In NIDDM patients, we observed a 3.49- and 4.52-fold increase of very-low-density lipoprotein (VLDL) and intermediate-density lipoprotein (IDL) apoB plasma concentrations, respectively (P<0.01). VLDL apoB production was increased by 41% (P<0.05) and fractional catabolic rate towards IDL and low-density lipoprotein (LDL) was decreased by 61% (P<0.05). The increased IDL apoB plasma concentration was also related to a major catabolic defect (-78%; P<0.01). For most patients, plasma LDL apoB concentration was comparable to that of controls. Nevertheless, LDL apoB metabolism was impaired in NIDDM subjects, with both a decreased LDL catabolic rate (-28%; P<0.05) and a trend towards a diminished synthesis.

CONCLUSION

NIDDM is associated with multiple apoB metabolism abnormalities that are potentially atherogenic. In addition to the increased number of circulating VLDL and IDL particles, the increased residence time observed on all apoB-containing lipoproteins may promote the development of atherosclerotic lesions, by potentiating their oxidizability.

Authors+Show Affiliations

INSERM U 498-Métabolisme des Lipoprotéines Humaines et Interactions Vasculaires, Faculté de Médecine, Dijon, France.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

10964160

Citation

Duvillard, L, et al. "Metabolic Abnormalities of Apolipoprotein B-containing Lipoproteins in Non-insulin-dependent Diabetes: a Stable Isotope Kinetic Study." European Journal of Clinical Investigation, vol. 30, no. 8, 2000, pp. 685-94.
Duvillard L, Pont F, Florentin E, et al. Metabolic abnormalities of apolipoprotein B-containing lipoproteins in non-insulin-dependent diabetes: a stable isotope kinetic study. Eur J Clin Invest. 2000;30(8):685-94.
Duvillard, L., Pont, F., Florentin, E., Galland-Jos, C., Gambert, P., & Vergès, B. (2000). Metabolic abnormalities of apolipoprotein B-containing lipoproteins in non-insulin-dependent diabetes: a stable isotope kinetic study. European Journal of Clinical Investigation, 30(8), 685-94.
Duvillard L, et al. Metabolic Abnormalities of Apolipoprotein B-containing Lipoproteins in Non-insulin-dependent Diabetes: a Stable Isotope Kinetic Study. Eur J Clin Invest. 2000;30(8):685-94. PubMed PMID: 10964160.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Metabolic abnormalities of apolipoprotein B-containing lipoproteins in non-insulin-dependent diabetes: a stable isotope kinetic study. AU - Duvillard,L, AU - Pont,F, AU - Florentin,E, AU - Galland-Jos,C, AU - Gambert,P, AU - Vergès,B, PY - 2000/8/30/pubmed PY - 2001/2/28/medline PY - 2000/8/30/entrez SP - 685 EP - 94 JF - European journal of clinical investigation JO - Eur J Clin Invest VL - 30 IS - 8 N2 - BACKGROUND: Kinetic abnormalities of apolipoprotein B (apoB)-containing lipoproteins in noninsulin-dependent diabetes mellitus (NIDDM) remain poorly understood. To get further insight into these abnormalities we performed a stable isotope kinetic experiment comparing the metabolism of apoB-containing lipoproteins in moderately severe NIDDM patients and healthy control subjects. METHODS: The study was performed in the fed state. Subjects underwent a primed infusion of 0.7 mg kg(-1) of L-[1-(13)C]leucine followed by a 16-h constant infusion of 0.7 mg kg(-1) h(-1). [13C]Leucine enrichment in apoB was measured by gas chromatography/combustion/isotope ratio mass spectrometry. RESULTS: In NIDDM patients, we observed a 3.49- and 4.52-fold increase of very-low-density lipoprotein (VLDL) and intermediate-density lipoprotein (IDL) apoB plasma concentrations, respectively (P<0.01). VLDL apoB production was increased by 41% (P<0.05) and fractional catabolic rate towards IDL and low-density lipoprotein (LDL) was decreased by 61% (P<0.05). The increased IDL apoB plasma concentration was also related to a major catabolic defect (-78%; P<0.01). For most patients, plasma LDL apoB concentration was comparable to that of controls. Nevertheless, LDL apoB metabolism was impaired in NIDDM subjects, with both a decreased LDL catabolic rate (-28%; P<0.05) and a trend towards a diminished synthesis. CONCLUSION: NIDDM is associated with multiple apoB metabolism abnormalities that are potentially atherogenic. In addition to the increased number of circulating VLDL and IDL particles, the increased residence time observed on all apoB-containing lipoproteins may promote the development of atherosclerotic lesions, by potentiating their oxidizability. SN - 0014-2972 UR - https://www.unboundmedicine.com/medline/citation/10964160/Metabolic_abnormalities_of_apolipoprotein_B_containing_lipoproteins_in_non_insulin_dependent_diabetes:_a_stable_isotope_kinetic_study_ L2 - https://onlinelibrary.wiley.com/resolve/openurl?genre=article&amp;sid=nlm:pubmed&amp;issn=0014-2972&amp;date=2000&amp;volume=30&amp;issue=8&amp;spage=685 DB - PRIME DP - Unbound Medicine ER -